Arcturus Therapeutics: Q2 Earnings Snapshot
ARCT-032 (CF) Phase 2 study enrollment remains on schedule; the decision to proceed into Phase 3 expected Q4 2026 ARCT-810 (OTC Deficiency) Phase 2 study enrollment and...
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today...
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today...
Strategic manufacturing agreement includes Phase 3 clinical supply and commercial manufacturing rights
Arcturus Therapeutics (NASDAQ:ARCT) President and CEO Joseph Payne outlined the company’s messenger RNA programs, vaccine approvals and upcoming clinical milestones during a presentation at the Jefferies...
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today...
Arcturus Therapeutics (NASDAQ:ARCT) executives highlighted progress in two rare-disease clinical programs and outlined a strengthened cash runway during the company’s first-quarter 2026 earnings call,...
Arcturus Therapeutics: Q1 Earnings Snapshot
Initiated enrollment (Q1 2026) earlier than expected for 12‑week cystic fibrosis (CF) open label Phase 2 study; lung function (ppFEV1 and LCI) is being monitored in Class I CF subjects ...